Obicetrapib-the Rebirth of CETP Inhibitors?
Curr Atheroscler Rep
; 26(10): 603-608, 2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-39150671
ABSTRACT
PURPOSE OF REVIEW To provide perspective on the current development status, and potential future role, of obicetrapib, a third-generation cholesterylester transfer protein (CETP) inhibitor. Obicetrapib has received recent attention following positive Phase II clinical trial data and initiation of Phase III trials for the treatment of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). RECENT FINDINGS:
The ROSE and ROSE2 trials are Phase II studies that examined the lipid lowering effects of obicetrapib in patients on pre-existing high-intensity statin therapy. Obicetrapib significantly reduced key dyslipidemia biomarkers including low density lipoprotein cholesterol (LDL-C), Apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) while increasing high-density lipoprotein cholesterol (HDL-C). Four phase III clinical trials, including a cardiovascular outcomes trial, are ongoing. Preliminary data for obicetrapib shows favorable effects on dyslipidemia, which could theoretically lead to a decrease in ASCVD clinical events. Short-term safety data in preliminary studies shows no significant safety signals.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cholesterol Ester Transfer Proteins
/
Anticholesteremic Agents
Limits:
Humans
Language:
En
Journal:
Curr Atheroscler Rep
Journal subject:
ANGIOLOGIA
Year:
2024
Type:
Article
Affiliation country:
United States